2-[(3S)-3-aminopyrrolidin-1-yl]-5-trifluoromethylpyridine | 202267-08-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(3S)-3-aminopyrrolidin-1-yl]-5-trifluoromethylpyridine
• 英文别名: (3S)-1-[5-(Trifluoromethyl)pyridin-2-yl]pyrrolidin-3-amine
• CAS: 202267-08-1
• 化学式: C₁₀H₁₂F₃N₃
• 分子量: 231.221
• InChiKey: YSMPURKYECKBKX-QMMMGPOBSA-N

物化性质

• 沸点：
  321.9±42.0 °C(Predicted)
• 密度：
  1.297±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  42.2
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2-[(3S)-3-aminopyrrolidin-1-yl]-5-trifluoromethylpyridine 、 9-[(3aS,4R,6R,6aR)-6-(tert-Butyl-dimethyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl]-6-iodo-9H-purine 在 N,N-二异丙基乙胺 作用下， 以 乙醇 为溶剂， 反应 24.0h， 以75%的产率得到{9-[(3aS,4R,6R,6aR)-6-(tert-Butyl-dimethyl-silanyloxymethyl)-2,2-dimethyl-tetrahydro-cyclopenta[1,3]dioxol-4-yl]-9H-purin-6-yl}-[(S)-1-(5-trifluoromethyl-pyridin-2-yl)-pyrrolidin-3-yl]-amine
  参考文献：
  名称：

  The sequel to a carbocyclic nucleoside synthesis: a divergent access to both arenediazonium ions and aryl triflates

  摘要：

  Depending on the amount of acid used, treating aryl-dialkyl triazenes of general structure 3 with triflic acid resulted in the formation of either the corresponding arenediazonium triflates 4 or aryl triflates 8 apparently by two different pathways, the latter conversion being favoured at high acid concentration. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.tetlet.2004.01.147
• 作为产物：
  描述：

  tert-butyl (S)-(1-(5-(trifluoromethyl)pyridin-2-yl)pyrrolidin-3-yl)carbamate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 以78 %的产率得到2-[(3S)-3-aminopyrrolidin-1-yl]-5-trifluoromethylpyridine
  参考文献：
  名称：

  First-in-Class Dual Hybrid Carbonic Anhydrase Inhibitors and Transient Receptor Potential Vanilloid 1 Agonists Revert Oxaliplatin-Induced Neuropathy

  摘要：

  DOI：

  10.1021/acs.jmedchem.2c01911

文献信息

• Novel processes for the preparation of adenosine compounds and intermediates thereto
  申请人：——

  公开号：US20030069423A1

  公开（公告）日：2003-04-10

  Novel processes for the preparation of adenosine compounds and intermediates thereto. The adenosine compounds prepared by the present processes may be useful as cardiovascular agents, more particularly as antihypertensive and anti-ischemic agents, as cardioprotective agents which ameliorate ischemic injury or myocardial infarct size consequent to myocardial ischemia, and as an antilipolytic agents which reduce plasma lipid levels, serum triglyceride levels, and plasma cholesterol levels. The present processes may offer improved yields, purity, ease of preparation and/or isolation of intermediates and final product, and more industrially useful reaction conditions and workability.

  新型的制备腺苷化合物及其中间体的方法。通过本方法制备的腺苷化合物可能作为心血管药物有用，更具体地作为降压和抗缺血药物，作为改善缺血性损伤或心肌梗死大小的心脏保护剂，以及作为降脂剂，可降低血浆脂质水平、血清甘油三酯水平和血浆胆固醇水平。本方法可能提供改善产率、纯度、制备和/或中间体和最终产品的分离的便利性，以及更具工业应用的反应条件和可操作性。
• Methods of treating insulin resistance syndrome and diabetes
  申请人：——

  公开号：US20030176390A1

  公开（公告）日：2003-09-18

  This invention is directed to methods of treating insulin resistance syndrome and diabetes in a patient in need thereof, comprising administering to said patient a pharmaceutically effective amount of a compound derived from adenosine and analogues thereof, or a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable prodrug thereof, an N-oxide thereof, a hydrate thereof or a solvate thereof, or a pharmaceutical composition comprising such compound.

  本发明涉及治疗胰岛素抵抗综合征和糖尿病的方法，包括向需要治疗的患者施用从腺苷和其类似物衍生的化合物的药效量，或其药用盐、药用前药、N-氧化物、水合物或溶剂化合物，或包含该化合物的药物组合物。
• [EN] PURINE DERIVATIVES AS ADENOSINE AL RECEPTOR LIGANDS<br/>[FR] DÉRIVÉS DE PURINE COMME LIGANDS DES RÉCEPTEURS A1 À L'ADÉNOSINE
  申请人：NOVARTIS AG

  公开号：WO2009050199A1

  公开（公告）日：2009-04-23

  Compounds of formula (I), their preparation and use as pharmaceuticals (I), wherein X, Y, and Z are as defined herein.

  公式（I）的化合物，其制备和用途作为药物（I），其中X、Y和Z的定义如下。
• [EN] OXALAMIDE HETEROBYCYCLIC COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY<br/>[FR] COMPOSÉS OXALAMIDE HÉTÉROBYCYCLIQUES ET COMPOSITIONS POUR LE TRAITEMENT D'AFFECTIONS ASSOCIÉES À UNE ACTIVITÉ DE STING
  申请人：IFM DUE INC

  公开号：WO2021067805A1

  公开（公告）日：2021-04-08

  This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit (e.g., antagonize) Stimulator of Interferon Genes (STING). Said chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) STING activation (e.g., STING signaling) contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also features compositions containing the same as well as methods of using and making the same.

  本公开涉及化学实体（例如，化合物或药用盐，和/或水合物，和/或共晶，和/或化合物的药物组合），其抑制（例如，拮抗）干扰素基因激活器（STING）。所述化学实体可用于治疗条件、疾病或障碍，其中增加（例如，过度）STING激活（例如，STING信号传导）对主体（例如，人类）的病理和/或症状和/或疾病或障碍的进展有贡献。本公开还涉及含有相同化学实体的组合物，以及使用和制备这些组合物的方法。
• Compounds having antihypertensive, cardioprotective anti-ischemic and antilipolytic properties
  申请人：——

  公开号：US20020099030A1

  公开（公告）日：2002-07-25

  This invention relates to adenosine derivatives and analogues which possess biological activity and are useful as anti-hypertensive, cardioprotective, anti-ischemic, and antilipolytic agents, to pharmaceutical compositions including such compounds, and to their use in treating hypertension, myocardial ischemia, ameliorating ischemic injury and myocardial infarct size consequent to myocardial ischemia, and treating hyperlipidemia and hypercholesterolemia, and to methods and intermediates used in the preparation of such compounds.

  本发明涉及腺苷衍生物和类似物，具有生物活性，可用作抗高血压、心脏保护、抗缺血和抗脂解作用的药物，包括这些化合物的制药组合物，以及它们在治疗高血压、心肌缺血、改善缺血损伤和心肌梗死大小，治疗高脂血症和高胆固醇血症方面的用途，以及用于制备这些化合物的方法和中间体。